ATTR amyloidosis related renal failure (eGFR<60 mL/min/m2) was reported to affect about 37% patients of FAP type I, which was caused by the most common mutation (TTR Val30Met).[12] And end-stage renal disease (ESRD) patients with TTRVal30Met mutation started dialysis at a mean age 51.5 years.[13] Besides, previous study revealed that screening of microalbuminuria might be an important predictor to assess ATTR amyloidosis onset and predict overt nephropathy as a noninvasive examination.[14] Few studies of long-term prognosis of p.Leu75Pro were reported. This evidence concerns the gene TTR and chronic kidney disease.